Search Results - "Raikhelkar, J"

Donor-Derived Cell-Free DNA is Associated with Cardiac Allograft Vasculopathy by Holzhauser, L., Fujino, T., Alenghat, F., Raikhelkar, J., Kim, G., Sayer, G., Uriel, N.

“…There is mounting evidence on the use of donor-derived cell-free DNA (dd-cfDNA) as a non-invasive tool to detect acute antibody and cellular mediated…”
Get full text

Donor-Derived Cell-Free DNA Does Not Correlate with Levels of Inflammation or Angiogenesis in a Stable Post Transplant Population by Holzhauser, L., Fujino, T., Nguyen, A., Alenghat, F., Raikhelkar, J., Kim, G., Sayer, G., Uriel, N.

“…Donor-derived cell-free DNA (dd-cfDNA) has recently been introduced as a novel marker of acute cellular and antibody mediated rejection. We hypothesized that…”
Get full text

Post-Heart Transplant Diabetes Mellitus: Incidence, Prevalence and Outcomes by Mazzone, S., Fujino, T., Nguyen, A., Chung, B., Smith, B., Raikhelkar, J., Kim, G., Sayer, G., Uriel, N.

“…De novo diabetes mellitus (DM) is a common complication of solid organ transplantation. However, studies about post-transplant DM (PTDM) following heart…”
Get full text

Optimal Cannula Positioning of Heart Mate 3 Left Ventricular Assist Device by Imamura, T., Nitta, D., Fujino, T., Nguyen, A., Narang, N., Chung, B., Holzhauser, L., Kim, G., Raikhelkar, J., Rodgers, D., Ota, T., Jeevanandam, V., Burkhoff, D., Sayer, G., Uriel, N.

“…Cannula position in HeartMate II and HVAD left ventricular assist devices (LVADs) is associated with clinical outcome. We aimed to investigate the clinical…”
Get full text

Residual Lung Injury Following HeartMate 3 Explantation for Heart Transplant by Kumai, Y., Takeda, K., Roth, Z., Fried, J., Raikhelkar, J., Clerkin, K., Colombo, P., Yuzefpolskaya, M., Topkara, V., Naka, Y., Uriel, N., Sayer, G.

“…Left ventricular assist device (LVADs) are commonly used as a bridge to transplantation. The HeartMate 3 (HM 3) is the most recently approved intrathoracic…”
Get full text

Heartmate 3 Implantation in Cancer Survivors with Advanced Heart Failure by Raikhelkar, J., Fried, J., Sumzin, N., Clerkin, K., Griffin, J., Sanchez, J., Marshall, D., Yuzefpolskaya, M., Colombo, P., Naka, Y., Takayama, H., Topkara, V., Sayer, G., Takeda, K., Uriel, N.

“…There are over 15 million Cancer Survivors (CSr) in the United States and this number is estimated to increase further with improvement in cancer therapeutics…”
Get full text

Hypogammaglobulinemia Following Heart Transplantation - Prevalence and Clinical Importance by Fujino, T., Kumai, Y., Nitta, D., Lourenco, L., Nguyen, A., Chung, B., Rodgers, D., Raikhelkar, J., Kim, G., Sayer, G., Uriel, N.

“…Hypogammaglobulinemia (HGG) can be identified in patients following solid organ transplantation and is thought to be predominantly due to immunosuppression…”
Get full text

Impact of Heart Failure Drug Therapy on GI Bleeding Rates in LVAD Recipients: An INTERMACS Analysis by Jennings, D.L., Truby, L., Fried, J., Clerkin, K., Griffin, J., Raikhelkar, J., Axsom, K., Lin, E., Haythe, J., Yuzefpolskaya, M., Colombo, P., Sayer, G., Farr, M., Takayama, H., Takeda, K., Naka, Y., Uriel, N., Topkara, V.K.

“…Gastrointestinal bleeding (GIB) remains a common and vexing complication of left ventricular assist device (LVAD) support. Recent single-center analyses…”
Get full text

Pulmonary Artery Pulsatility Index (PAPi) is a Predictor of Right Ventricular Assist Device (RVAD) Use Following HeartMate 3 LVAD Implantation by Marshall, D., Malick, A., Truby, L., Butler, C., Griffin, J., Clerkin, K., Fried, J., Raikhelkar, J., Yuzefpolskaya, M., Colombo, P., Sayer, G., Takayama, H., Takeda, K., Naka, Y., Farr, M., Uriel, N., Topkara, V.K.

“…Pulmonary artery pulsatility index (PAPi) recently emerged as a predictor of right ventricular failure after Heartmate II LVAD Implantation. Clinical utility…”
Get full text

Prognostication of Residual Mitral Regurgitation or Aortic Insufficiency after Invasive Hemodynamic Ramp Optimization by Mehta, N., Fujino, T., Belkin, M., DelaCruz, M., Yu, D., Holzhauser, L., Rodgers, D., Smith, B., Kalantari, S., Sarswat, N., Chung, B., Nguyen, A., Uriel, N., Raikhelkar, J., Sayer, G., Song, T., Ota, T., Jeevanandam, V., Kim, G., Grinstein, J.

“…LVAD speed optimization via invasive ramp studies have been shown to reduce LVAD related morbidity. Many LVAD implanting centers use non-invasive…”
Get full text

Biomarkers of Inflammation and Oxidative Stress in HeartMate II vs HeartMate 3 Patients by Mondellini, G.M., Braghieri, L., Javaid, A., Pinsino, A., Uriel, N., Sayer, G.T., Raikhelkar, J.K., Takeda, K., Naka, Y., Demmer, R.T., Yuzefpolskaya, M., Colombo, P.C.

“…Inflammation and oxidative stress have been implicated in the pathophysiology of hemocompatibility related adverse events (HRAEs) in left ventricular assist…”
Get full text

Outflow Cannula Systolic Slope as a Predictor of Myocardial Recovery Leading to Successful LVAD Decommission: A Case Series by Yu, D., Kruse, E., Rodgers, D., Holzhauser, H., Sarswat, N., Smith, B., Kalantari, S., Chung, B., Nguyen, A.B., Mehta, N., Raikhelkar, J., Sayer, G., Uriel, N., Song, T., Ota, T., Jeevanandam, V., Kim, G., Grinstein, J.

“…In patients implanted with durable left ventricular assist device (LVAD), the incidence of myocardial recovery leading to device explant or decommission is…”
Get full text

De-Novo Human Leukocyte Antigen Allosensitization on HeartMate 3 versus HeartMate II Left Ventricular Assist Device Recipients by Jain, R., Habal, M., Restaino, S., Latif, F., Truby, L., Clerkin, K., Raikhelkar, J., Fried, J., Masoumi, A., Yuzefpolskaya, M., Colombo, P., Sayer, G., Takayama, H., Takeda, K., Naka, Y., Farr, M., Uriel, N., Topkara, V.K.

“…MOMENTUM 3 trial demonstrated superiority of Heartmate 3 (HM 3) compared to Heartmate II (HM 2) with regards to hemocompatibility, however, their differential…”
Get full text

Increased Right Ventricular Assist Device (RVAD) Utilization in Patients with HeartMate 3 Left Ventricular Assist Device (LVAD) in the Post-Approval Era by Marshall, D., DeFilippis, E., Truby, L., Malick, A., Butler, C., Griffin, J., Clerkin, K., Fried, J., Raikhelkar, J., Yuzefpolskaya, M., Colombo, P., Sayer, G., Takeda, K., Takayama, H., Naka, Y., Farr, M., Uriel, N., Topkara, V.K.

“…MOMENTUM 3 trial excluded patients with planned biventricular support prior to enrollment and 4.2% right ventricular failure requiring RVAD in Heartmate 3 (HM…”
Get full text

Absence of Aortic Valve Opening after Hemodynamic Ramp Optimization Study Does Not Impact LVAD Morbidity of Mortality by Mehta, N., Fujino, T., Dela Cruz, M., Holzhauser, L., Rodgers, D., Kalantari, S., Smith, B., Sarswat, N., Nguyen, A., Chung, B., Uriel, N., Raikhelkar, J., Sayer, G., Ota, T., Song, T., Jeevanandam, V., Kim, G., Grinstein, J.

“…Aortic valve opening in patients supported by left ventricular assist devices (LVAD) preserves native valve geometry and structure and reduces rates of aortic…”
Get full text

Outcomes of Patients Bridged with Acute Mechanical Circulatory Support Devices to HeartMate 3 by Fried, J.A., Masoumi, A., Witer, L., Kaku, Y., Sumzin, N., Roth, Z., Clerkin, K.J., Griffin, J.M., Raikhelkar, J., Sanchez, J., Marshall, D., Karmpaliotis, D., Kirtane, A.J., Yuzefpolskaya, M., Colombo, P.C., Topkara, V., Takayama, H., Naka, Y., Sayer, G.T., Uriel, N., Takeda, K.

“…Acute mechanical circulatory support devices (MCSD) are increasingly being used to stabilize and optimize patients for durable left ventricular assist device…”
Get full text

Successful Use of Veno-Arterial Extracorporeal Membrane Oxygenation as a Bridging Strategy in INTERMACS 1 Patients Undergoing HeartMate 3 LVAD Implantation by Fried, J.A., Sumzin, N., Witer, L., Kaku, Y., Roth, Z., Masoumi, A., Raikhelkar, J.K., Clerkin, K.J., Griffin, J.M., Sanchez, J., Yuzefpolskaya, M., Kirtane, A.J., Topkara, V., Colombo, P.C., Takayama, H., Naka, Y., Sayer, G.T., Brodie, D., Takeda, K., Uriel, N.

“…Veno-arterial extracorporeal membrane oxygenation (ECMO) is increasingly used to treat refractory cardiogenic shock, but prior reports have demonstrated poor…”
Get full text

Elevated Serum C-reactive Protein (CRP) Level Predicts Increased Post-Implant Mortality in Patients Undergoing HeartMate 3 LVAD Implantation by Batra, J., Marshall, D., Jennings, D., Truby, L., DeFilippis, E., Malick, A., Butler, C., Griffin, J., Masoumi, A., Clerkin, K., Raikhelkar, J., Fried, J., Yuzefpolskaya, M., Colombo, P., Sayer, G., Takayama, H., Takeda, K., Naka, Y., Farr, M., Topkara, V.K., Uriel, N.

“…C-reactive protein (CRP) emerged as a biomarker of inflammation in heart failure patients and associated with increased morbidity and mortality. We…”
Get full text

Pre LVAD CPET as Predictor of INTERMACS Profile and Early Outcomes Post LVAD by Brailovsky, Y., Mondellini, G.M., Javaid, A., Braghieri, L., Kleet, A.C., Shargarodskaya, R., Raikhelkar, J.K., Pineda, M.F., Fried, J.A., Kim, D.S., Takeda, K., Naka, Y., Sayer, G., Uriel, N., Goldsmith, R.L., Colombo, P.C., Yuzefpolskaya, M.

“…Cardiopulmonary Exercise Testing (CPET) is the clinical standard to select HF pts for cardiac replacement therapy. INTERMACS profile is used to risk stratify…”
Get full text

Increased Rate of Pump Thrombosis and Cardioembolic Events Following Ventricular Tachycardia Ablation in Patients Supported with Left Ventricular Assist Devices by Grinstein, J, Garan, A.R, Flatley, E, Kim, G.H, Mai, X, Sarswat, N, Kalantari, S, Adatya, S, Raikhelkar, J, Sayer, G, Oesterle, A, Jeevanandam, V, Moss, J, Uriel, N

Get full text